How well do FDA warning and untitled letters address what the agency sees as noncompliant activities by unproven stem cell clinics and supplier firms? One might think these letters work well given the implicit threat that not complying with them could lead to more severe action. For instance, the FDA can seek injunctions. Yet, that […] The post Weekly reads: FDA warning, Capricor pub vs. AdCom, stem cells can count, hydra regeneration appeared first on The Niche .